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Purpose or Objective: Transanal Endoscopic Microsurgery 
(TEM) and Radiotherapy in Early Rectal Cancer (TREC) [1][2] 
is a randomised phase II feasibility study to compare radical 
TEM surgery versus short course pre-operative radiotherapy 
(25Gy in 5 fractions over 5 days) with delayed local excision 
for treatment of early rectal cancer. 
The QA programme for TREC is co-ordinated by the UK 
Radiotherapy Trials Quality Assurance (RTTQA) group [3][4]. 
We describe the development of a standardised analysis 
pipeline and the results of this analysis. 
 
Material and Methods: To ensure consistency and therefore 
comparability between radiotherapy centres involved in 
TREC, a detailed radiotherapy protocol was developed. To 
assess the quality of the plans, 3 (PTVmin, PTVmax, 
ICRUmax) quantities were measured and recorded. Further 
investigation was carried out if the relevant objective was 
not met. 
TEMS patients in TREC were treated across 18 UK centres. 
Radiotherapy plan data was submitted for each of the 87 TEM 
patients in DICOM format and processed with the 
Computational Environment for Radiotherapy Research 
(CERR) software [5]. This enabled i) outlining of target and 
organ-at-risk structures, ii) dose distribution and dose volume 
histograms to be assessed (independently) and iii) data 
format standardisation and automated analysis.  
 
Results: 
 
 
Table 1 shows the ROI objectives outlined in the TREC 
protocol. Figure 1 shows the distribution of PTV coverage for 
the 87 TEM patients analysed. All plans achieved D2%<110% 
(Figure 1, marker A) and 95% of plans achieved D5%<105% (B). 
Cases of poor coverage (C) were investigated and in 4 cases it 
was found that the outlined PTV extended beyond the patient 
surface. In these cases PTV was retracted to within the 
patient surface and coverage was recalculated. 
 
Conclusion: Deviation from the clinical trial protocol has the 
potential to confound the study question and quality 
assurance is therefore essential when comparing different 
treatments. A high level of conformance was found across the 
18 treating centres, with 95% of plans achieving both the 
minimum and maximum PTV objectives. Our analysis of the 
radiotherapy plans demonstrates good understanding and 
adherence to the TREC protocol. 
STAR-TREC is an upcoming trial that will amend and extend 
the TREC pilot. RTTQA findings from TREC will be used to 
strengthen and improve the STAR-TREC protocol, for 
example, use of standardised structure names and use of 
plan-optimisation PTVs to assess target coverage. 
 
References: 
 
 
EP-1919  
A cost-effective and fast end-to-end test for treatment 
accuracy evaluation 
A. Wopereis
1UMC Utrecht, Radiotherapy, Utrecht, The Netherlands 
1, K. Ishakoglu1, E. Seravalli1, J. Wolthaus1 
 
Purpose or Objective: End-to-end tests are used to measure 
the overall accuracy of the radiation therapy chain, excluding 
patient specific factors. An end-to-end test is a prerequisite 
to the overall success of any IGRT program. In this work the 
performance of a cost-effective and fast end-to-end test to 
assess the geometrical accuracy of the radiotherapy workflow 
is described.  
 
Material and Methods: The in-house developed phantom for 
end-to-end testing is depicted in figure 1a. It consists of two 
Perspex slabs in which a piece of Gafchromic EBT3 film of 
4x4cm2 can be placed in. Two notches tighten the film and 
determine the center and the orientation of the 
phantom/film respectively. The phantom can be positioned 
in such a way to have the film in the coronal and sagittal 
orientation. The total weight of the phantom is about 1kg. A 
high resolution computed tomography (CT) scan is made of 
the phantom and a treatment plan (figure 1b) including 
collimator, gantry and table rotations is computed on this CT. 
The treatment plan is sent to the linear accelerator. 
Simulating an actual patient treatment, the phantom is set 
up on the treatment table using the lasers. Then, cone beam 
CT guidance is used to adjust the phantom’s position with 
respect to the planning CT. After applying the suggested 
table shift the plan is irradiated. The films are analyzed using 
an in-house written Excel macro. The shift required to align 
the film with the calculated dose plane represents the 
targeting error. The use of the described phantom for end-to-
end testing was compared against two commercial available 
phantoms. 
 
 
 
Results: The phantom is light, easy to handle and to set up. 
Moreover, it is cheap compared to available commercial 
systems. The phantom allows to assess the overall 
geometrical accuracy of the treatment chain with sub mm 
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accuracy. The end-to-end test procedure requires on average 
70 min preparation time, 30 min at the linear accelerator, 20 
min analysis and administration. It allows end-to-end testing 
to be performed more frequently to assure the accuracy over 
time.  
 
Conclusion: The developed end-to-end test is quick, cost-
effective and easy to implement clinically. It allows to 
frequently highlight geometrical inaccuracies in an image-
guided radiation therapy environment.  
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Purpose or Objective: The Global Harmonisation Group was 
created in 2009 to harmonise and improve the quality 
assurance (QA) of radiation therapy implemented worldwide 
in multi-institutional clinical trials. The aim is to achieve a 
consistent platform to provide and share QA processes in 
clinical trials such that the workload for both the institutions 
and the QA groups is reduced and streamlined. As part of this 
aim, the group reviewed their reporting techniques to better 
understand each other’s approaches and agree on core 
information which would be included as part of future 
creation of a standard template. This could potentially lead 
to the ability to use each other’s reports in lieu of 
unnecessary duplication 
 
Material and Methods: A survey was created to find a list of 
core information which could be included in future dosimetry 
credentialing reports. Answers were requested to give 
opinion from each group as to what should be included as a 
minimum in these reports. Some QA groups use site visits or 
postal phantoms, whereas some use a virtual phantom (i.e. 
local QA measurement) and others use both. The questions 
were divided to allow responses for both types. Questions 
were circulated amongst the groups beforehand and all 
comments and contributions were incorporated. 
 
Results: All seven current member groups replied. Results 
were divided into three categories, 1)information which all 
groups agreed should be included 2)information which the 
majority use and the others often use which could be 
discussed as being agreed on inclusion and 3)information 
which was not used by all groups, but which could be used by 
those who did (see table 1). 
 
Table 1 Agreed information in clinical trial QA group reports 
 
Conclusion: The survey showed that that there is a wide 
variation in the information currently provided in the reports 
from the various QA organisations, which may hamper their 
mutual acceptance. Following discussion there were several 
pieces of information which were agreed should always be 
included and these constitute the beginning of an agreed list 
of included core information. There are several more pieces 
of information which the majority always include and the 
others use often or sometimes. These could be discussed to 
understand when and why they are not used and perhaps 
considered for inclusion. There are some others where not all 
members use the information because they do not use a 
gamma index analysis, however these could be included for 
those who do use the gamma index. There is also some 
information which sometimes included, but which is always 
included when needed. These cases will be discussed and 
decided if these should be included in specific cases, perhaps 
including a flowchart to aid standardisation. Some groups 
have already reviewed or are in the process of reviewing 
their reports to ensure inclusion of core information. 
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Purpose or Objective: To present an overview and the 
current status of Novalis Certification, which provides a 
comprehensive and independent assessment of safety and 
quality in stereotactic radiosurgery (SRS) and stereotactic 
body radiation therapy (SBRT), ensuring the highest standards 
and consistency of practice. 
 
Material and Methods: The Novalis Certification program 
includes a review of SRS/SBRT program structure, adequacy 
of personnel resources and training, appropriateness and use 
of technology, program quality management, patient-specific 
quality assurance and equipment quality control. Currently 
ten auditors support the program, with six in North America, 
three in Europe and one in Asia, each bringing a minimum of 
a decade of experience in stereotactic practice. Centres 
applying for Novalis Certification complete a self-study 30 
days prior to a scheduled one-day site visit by one to two 
reviewers. Reviewers generate a descriptive 77-point report 
which is reviewed and voted on by a multidisciplinary expert 
panel of 3 medical physicists, 2 radiation oncologists and 2 
neurosurgeons. Outcomes of reviews may include mandatory 
